Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(9 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama Colorado Blood Cancer Institute, Denver, Colorado University of Iowa, Iowa City, Iowa University of North Carolina, Chapel Hill, North Carolina Oncology Hematology Care, Cincinnati, Ohio SCRI Oncology Partners, Nashville, Tennessee Virginia Oncology Associates, Norfolk, Virginia University of Wisconsin Clinical Science Center, Madison, Wisconsin Medical College of Wisconsin, Milwaukee, Wisconsin Age range
19 Years and older
Last updated January 2026